Hunan Fangsheng Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Xiaoli Zhou
Chief executive officer
CN¥1.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.8yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Hunan Fangsheng Pharmaceutical's (SHSE:603998) Earnings Are Weaker Than They Seem
Nov 04
The Market Doesn't Like What It Sees From Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Earnings Yet
Jun 06Earnings Troubles May Signal Larger Issues for Hunan Fangsheng Pharmaceutical (SHSE:603998) Shareholders
Apr 30Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) 34% Share Price Surge Not Quite Adding Up
Mar 04CEO
Xiaoli Zhou (51 yo)
2.8yrs
Tenure
CN¥1,170,300
Compensation
Ms. Xiaoli Zhou serves as General Manager of the Board at Hunan Fangsheng Pharmaceutical Co., Ltd and serves as its Chairman since March 04, 2022.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman | 2.8yrs | CN¥1.17m | no data | |
| Deputy GM & Director | 10.5yrs | CN¥650.90k | no data | |
| Independent Director | 1.3yrs | CN¥13.70k | no data | |
| Independent Director | 4yrs | CN¥50.00k | no data | |
| Independent Director | 3.2yrs | CN¥50.00k | no data | |
| Chairman of the Supervisory Board | 4yrs | no data | no data | |
| Supervisor | 4yrs | no data | no data | |
| Director | 2.3yrs | CN¥414.70k | 0.035% CN¥ 1.5m | |
| Employee Supervisor | 2.2yrs | no data | no data |
3.2yrs
Average Tenure
45yo
Average Age
Experienced Board: 603998's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 09:08 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Fangsheng Pharmaceutical Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wentao Li | Citic Securities Co., Ltd. |
| Kehan Meng | Haitong International Research Limited |
| Wenxin Yu | Haitong International Research Limited |